<DOC>
	<DOCNO>NCT00474188</DOCNO>
	<brief_summary>To evaluate safety efficacy lenalidomide ( Revlimid ® ) combination dexamethasone subject relapse refractory diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>A Study Evaluate Lenalidomide Combined With Dexamethasone Relapsed Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>Non-Hodgkin 's lymphoma ( NHL ) divide two general prognostic group : indolent lymphomas aggressive lymphoma . Indolent lymphoma relatively good prognosis , median survival time long 10 year , usually curable advanced stage . Aggressive NHL constitute half case NHL North America Western Europe . Of aggressive lymphoma , diffuse large B-cell lymphoma ( DLBCL ) common type , account 30 percent newly diagnose case . The aggressive type NHL short natural history ; approximately 50-60 % subject cure combination chemotherapy regimens . Even recent advance , many patient advanced stage DLBCL cure conventional therapy . This leave subset subject eventually relapse refractory treatment . Due variation clinical behavior different type aggressive NHL , important test lenalidomide DLBCL . Other study address activity lenalidomide type aggressive lymphoma , well indolent NHL . It important test lenalidomide combination therapy . This study focus treat subject relapse refractory DLBCL use oral lenalidomide combination oral dexamethasone .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Biopsyproven diffuse large Bcell nonHodgkin 's lymphoma Relapsed refractory previous therapy nonHodgkin 's lymphoma Measurable disease cross sectional imaging least 2 cm long diameter ECOG performance score 0,1 2 Willing follow pregnancy precaution Any follow laboratory abnormality . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) . Platelet count &lt; 60,000/mm3 ( 60 x 109/L ) . Serum SGOT/AST SGPT/ALT 5.0 x upper limit normal ( ULN ) . Serum total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) . Subjects candidate willing undergo autologous stem cell transplant . History active CNS lymphoma within previous 3 month Subjects willing unable take DVT prophylaxis History malignancy within past year Positive HIV active Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Celgene</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Diffuse Large B-cell lymphoma</keyword>
	<keyword>Non-Hodgkins lymphoma</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Response Rate</keyword>
	<keyword>Tumor Control Rate</keyword>
	<keyword>Duration Response</keyword>
	<keyword>Time Progression</keyword>
	<keyword>Progression-free survival safety</keyword>
</DOC>